t315i market

Has anyone looked at the FDA ODAC panel? I saw it through bloomberg (takes about 4 hours). The company, as well as analysts and people posting here, have grossly overestimated the market size. I'll paraphrse the female ODAC panel member who is the T315i patient advocacy group leader who said that she commends the company for developing a drug that will treat only 200 T315i patients in the USA. Previous company estimates were 2500 patients. Somehow, i choose to believe the head of the patient advocacy group for T315i over the company.

i use to own but sold when saw briefing docs. The quesiton is not will it get approved, the question is 'can this be a commercial success?"

here is the link, you need access to bloomberg

http://www.bloomberg.com/avp/avp.htm?N=video&T=FDA%20Oncology%20Committee%20Reviews%20ChemGenex's%20Omapro%20&clipSRC=mms://media2.bloomberg.com/cache/vvtpurz.drlQ.asf